| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
| Products Intro: |
Product Name:Anatibant
CAS:209733-45-9
Purity:Typically NLT 98%
|
Anatibant manufacturers
- Anatibant
-
- $1670.00 / 25mg
-
2025-07-17
- CAS:209733-45-9
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Anatibant Basic information |
| Product Name: | Anatibant | | Synonyms: | anatibant;(2s)-n-(3-(4-carbamimidoylbenzamido)propyl)-1-(2,4-dichloro-3-((2,4-dimethyl-8-quinolyloxy)methyl)phenylsulfonyl)pyrrolidine-2-carboxamide;2-PYRROLIDINECARBOXAMIDE, N-[3-[[4-(AMINOIMINOMETHYL)BENZOYL]AMINO]PROPYL]-1-[[2,4-DICHLORO-3-[[(2,4-DIMETHYL-8-QUINOLINYL)OXY]METHYL]PHENYL]SULFONYL]-, (2S)-;Anatibant [inn];Unii-clo4jrd21f;(S)-N-(3-(4-Carbamimidoylbenzamido)propyl)-1-((2,4-dichloro-3-(((2,4-dimethylquinolin-8-yl)oxy)methyl)phenyl)sulfonyl)pyrrolidine-2-carboxamide | | CAS: | 209733-45-9 | | MF: | C34H36Cl2N6O5S | | MW: | 711.66 | | EINECS: | | | Product Categories: | | | Mol File: | 209733-45-9.mol |  |
| | Anatibant Chemical Properties |
| density | 1.44±0.1 g/cm3(Predicted) | | pka | 14.09±0.46(Predicted) |
| | Anatibant Usage And Synthesis |
| Uses | Anatibant (LF 16-0687; XY-2405) is a selective non-peptide bradykinin B2 receptor antagonist. Anatibant binds to the human, rat and guinea-pig recombinant B2 receptor with Ki values of 0.67 nM, 1.74 nM and 1.37 nM, respectively. Anatibant crosses the blood-brain barrier (BBB). Anatibant can be used in research on brain damage diseases[1][2]. | | Definition | ChEBI: Anatibant is a proline derivative. | | in vivo | Anatibant (3 mg/kg; subcutaneous bolus; injection 15 min and 8 h after trauma, respectively) significantly reduces intracranial pressure (ICP) and of contusion volume 24 h after trauma in treated mice[1]. | Animal Model: | Male C57/Bl6 mice (25-28 g) were subjected to Controlled Cortical Impact trauma (CCI)[1] | | Dosage: |
3 mg/kg | | Administration: | Subcutaneous bolus; injection 15 min and 8 h after trauma, respectively | | Result: | Demonstrated a significant reduction of ICP and of contusion volume 24 h after trauma in treated mice. |
| | IC 50 | Bradykinin B2 Receptor (B2R): 0.67 nM (Ki, human recombinant B2 receptor); Bradykinin B2 Receptor (B2R): 1.74 nM (Ki, Rat recombinant B2 receptor); Bradykinin B2 Receptor (B2R): 1.37 nM (Ki, Guinea-pig recombinant B2 receptor) | | References | [1] Klaus Zweckberger, et al. Anatibant, a selective non-peptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury. Neurosci Lett. 2009 Apr 24;454(2):115-7. DOI:10.1016/j.neulet.2009.02.014
[2] D Pruneau, et al. Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist. Immunopharmacology. 1999 Sep;43(2-3):187-94. DOI:10.1016/s0162-3109(99)00128-9 |
| | Anatibant Preparation Products And Raw materials |
|